SecBot SecBot
Biotech Drug Report Generated Nov 11, 2026

OP-3136

OLMA·Olema Oncology
NEUTRAL
Drug Impact Rating4/10
Trial phase
Phase 1/1b/2
Time to market
OP-3136 is in Phase 1/1b/2 clinical trials. If development proceeds successfully, a potential approval would likely be several years away, contingent on completing Phase 2/3 trials.
Why 4/10
The next hard, dated catalyst for OP-3136 is the presentation of combination data from the palazestrant and OP-3136 programs at the San Antonio Breast Cancer Symposium (SABCS) in December 2026. This is a scientific conference presentation of early-stage data, not a pivotal readout or regulatory decision. OP-3136 is a Phase 1/1b/2 pipeline asset behind Olema's lead drug palazestrant (Phase 3), so even positive SABCS data would be a modest catalyst for the stock. ImpactScore is 4.
Actionable Insight NEUTRAL

The next catalyst for OP-3136 is the SABCS presentation in December 2026, where combination data with palazestrant will be shown. Positive data could support the combination strategy and boost confidence in the broader pipeline, but the stock's primary near-term binary is the Phase 3 OPERA-01 palazestrant readout expected in Q1 2027. OP-3136 remains an early-stage pipeline asset, and its data at SABCS is unlikely to be a standalone stock-moving event.

Price Chart

Loading chart...

Executive Summary

OP-3136 is an oral KAT6 inhibitor in Phase 1/1b/2 development by Olema Pharmaceuticals (Nasdaq: OLMA) for breast cancer and potentially other solid tumors. Initial Phase 1 monotherapy data presented at ASCO in May 2026 showed a clean safety profile (no dose-limiting toxicities, no treatment-related discontinuations) and tumor shrinkage in nearly two-thirds of evaluable patients across multiple cancer types. A Phase 1b/2 combination study with palazestrant (Olema's lead SERD/CERAN) is enrolling, and a collaboration with Bayer was signed to test OP-3136 with darolutamide in prostate cancer. The next catalyst is a combination data presentation at the San Antonio Breast Cancer Symposium in December 2026. However, OP-3136 is an early-stage pipeline asset; Olema's primary near-term value driver is the Phase 3 OPERA-01 palazestrant readout expected in Q1 2027.

How It Works

OP-3136 is an oral small-molecule drug that inhibits KAT6, an enzyme involved in epigenetic regulation (chemical modifications that turn genes on or off without changing the DNA sequence). KAT6 is overactive in breast cancer and other solid tumors, driving cancer growth. By blocking KAT6, OP-3136 aims to slow or stop tumor growth. It is being studied alone and in combination with other cancer drugs.

Trial Status

Phase 1 monotherapy dose-escalation study has completed with initial data presented at ASCO June 2026. A Phase 1b/2 study evaluating OP-3136 in combination with fulvestrant and palazestrant is actively enrolling patients. A separate Phase 1b study in combination with Bayer's darolutamide for metastatic castration-resistant prostate cancer is expected to initiate in H2 2026.

The Two-Sided Case

▲ Bull Case6
Initial Phase 1 monotherapy data at ASCO 2026 showed OP-3136 was well-tolerated with no dose-limiting toxicities and no treatment-related discontinuations, a clean safety profile.
Nearly two-thirds of evaluable patients experienced tumor shrinkage across multiple solid tumor types, suggesting broad anti-tumor activity.
Preclinical data showed synergistic anti-tumor activity when OP-3136 is combined with palazestrant in ER+/HER2- breast cancer models, supporting a combination strategy.
A clinical trial collaboration with Bayer was signed to evaluate OP-3136 in combination with darolutamide for metastatic castration-resistant prostate cancer, expanding the addressable market beyond breast cancer.
Olema had $413.8M in cash at Q3 2026, providing runway to advance both palazestrant and OP-3136 programs.
Analyst consensus is strongly bullish: 16 Buy/Strong Buy ratings, 2 Hold, 0 Sell, with a mean price target of $36.50 (396% implied upside from $7.36).
▼ Bear Case5
OP-3136 is still in early-stage Phase 1/1b/2 development; the drug is years away from any regulatory filing or approval.
KAT6 inhibitors are a novel mechanism with no approved drugs in the class, so clinical proof-of-concept remains unvalidated.
Olema's stock has fallen sharply from its 52-week high of $36.26 to $7.27, reflecting investor disappointment over the OPERA-01 data delay into 2027 and institutional exits by RA Capital, Jennison, and Polar Capital.
OP-3136 is a pipeline asset behind the lead drug palazestrant; the company's near-term value depends almost entirely on the Phase 3 OPERA-01 readout, not OP-3136.
The Bayer collaboration for prostate cancer is a small Phase 1b study (~36 patients) and does not derisk the program substantially.

Upcoming Catalysts

  • December 2026: Presentation of combination data from the palazestrant and OP-3136 programs at the San Antonio Breast Cancer Symposium (SABCS)
  • H2 2026: Initiation of Phase 1b study of OP-3136 in combination with darolutamide for prostate cancer (Bayer collaboration)
  • Ongoing: Enrollment and future data readouts from the Phase 1b/2 combination study with palazestrant

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Olema Oncology PRESS-RELEASE OLMA ·Originating report

Sources · 7

Hover a chip for the title
1 markets.financialcontent.com2 msn.com3 manilatimes.net4 markets.businessinsider.com5 markets.businessinsider.com6 morningstar.com7 streetinsider.com